Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic bre...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1158981/full |
| _version_ | 1797833078331146240 |
|---|---|
| author | Víctor Albarrán Jesús Chamorro Javier Pozas María San Román Diana Isabel Rosero Cristina Saavedra María Gion Alfonso Cortés Elena Escalera Eva Guerra Elena López Miranda María Fernández Abad Noelia Martínez Jañez |
| author_facet | Víctor Albarrán Jesús Chamorro Javier Pozas María San Román Diana Isabel Rosero Cristina Saavedra María Gion Alfonso Cortés Elena Escalera Eva Guerra Elena López Miranda María Fernández Abad Noelia Martínez Jañez |
| author_sort | Víctor Albarrán |
| collection | DOAJ |
| description | PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic breast cancer in carriers of germline BRCA mutations, which are found in approximately 6% of patients with breast cancer. We report the case of a patient with metastatic breast cancer, carrier of a germline mutation in BRCA2, with a complete response to first-line treatment with talazoparib, maintained after 6 years. To the best of our knowledge, this is the longest response reported with a PARP inhibitor in a BRCA-mutated tumor. We have made a review of literature, regarding the rationale for PARP inhibitors in carriers of BRCA mutations and their clinical relevance in the management of advanced breast cancer, as well as their emerging role in early stage disease, alone and in combination with other systemic therapies. |
| first_indexed | 2024-04-09T14:17:57Z |
| format | Article |
| id | doaj.art-e86c0ec339974c8c8252d1bb6e51b17f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T14:17:57Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e86c0ec339974c8c8252d1bb6e51b17f2023-05-05T05:58:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-05-011310.3389/fonc.2023.11589811158981Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literatureVíctor AlbarránJesús ChamorroJavier PozasMaría San RománDiana Isabel RoseroCristina SaavedraMaría GionAlfonso CortésElena EscaleraEva GuerraElena López MirandaMaría Fernández AbadNoelia Martínez JañezPARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic breast cancer in carriers of germline BRCA mutations, which are found in approximately 6% of patients with breast cancer. We report the case of a patient with metastatic breast cancer, carrier of a germline mutation in BRCA2, with a complete response to first-line treatment with talazoparib, maintained after 6 years. To the best of our knowledge, this is the longest response reported with a PARP inhibitor in a BRCA-mutated tumor. We have made a review of literature, regarding the rationale for PARP inhibitors in carriers of BRCA mutations and their clinical relevance in the management of advanced breast cancer, as well as their emerging role in early stage disease, alone and in combination with other systemic therapies.https://www.frontiersin.org/articles/10.3389/fonc.2023.1158981/fullbreast cancerBRCAgermlinePARP inhibitorsolaparibtalazoparib |
| spellingShingle | Víctor Albarrán Jesús Chamorro Javier Pozas María San Román Diana Isabel Rosero Cristina Saavedra María Gion Alfonso Cortés Elena Escalera Eva Guerra Elena López Miranda María Fernández Abad Noelia Martínez Jañez Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature Frontiers in Oncology breast cancer BRCA germline PARP inhibitors olaparib talazoparib |
| title | Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature |
| title_full | Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature |
| title_fullStr | Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature |
| title_full_unstemmed | Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature |
| title_short | Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature |
| title_sort | maintained complete response to talazoparib in a brca 2 mutated metastatic luminal breast cancer case report and review of literature |
| topic | breast cancer BRCA germline PARP inhibitors olaparib talazoparib |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1158981/full |
| work_keys_str_mv | AT victoralbarran maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT jesuschamorro maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT javierpozas maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT mariasanroman maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT dianaisabelrosero maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT cristinasaavedra maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT mariagion maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT alfonsocortes maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT elenaescalera maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT evaguerra maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT elenalopezmiranda maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT mariafernandezabad maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature AT noeliamartinezjanez maintainedcompleteresponsetotalazoparibinabrca2mutatedmetastaticluminalbreastcancercasereportandreviewofliterature |